Heterologous immunity (HI) is a consequence of an encounter with a specific antigen, which
can alter the subsequent immune response to a different antigen. This can happen at the …

This review discusses three inter-related topics:(1) the immaturity of the neonatal and infant
immune response;(2) heterologous immunity, where prior infection history with unrelated …

Immunotherapy has become one of the most promising avenues for cancer treatment,
making use of the patient's own immune system to eliminate cancer cells. Clinical trials with …

T-cell-based immunotherapies hold tremendous potential in the fight against cancer, thanks
to their capacity to specifically targeting diseased cells. Nevertheless, this potential has been …

The recognition of antigenic peptide-MHC (pMHC) molecules by T-cell receptors (TCR)
initiates the T-cell mediated immune response. Structural characterization is key for …

The class I major histocompatibility complex (MHC) is capable of binding peptides derived
from intracellular proteins and displaying them at the cell surface. The recognition of these …

T-cell receptor (TCR) molecules play a central role in adaptive cellular immunity, enabling T-
cell lymphocytes to recognize peptide-loaded Major Histocompatibility Complexes (pMHCs) …

The Class I Major Histocompatibility Complex (MHC) is a central protein in immunology as it
binds to intracellular peptides and displays them at the cell surface for recognition by T-cells …

The immune system is constantly challenged, being required to protect the organism against
a wide variety of infectious pathogens and, at the same time, to avoid autoimmune disorders …

Human leukocyte antigen class I (HLA-I) molecules bind and present peptides at the cell
surface to facilitate the induction of appropriate CD8+ T cell-mediated immune responses to …